X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/inxmed-enters-license-agreement-with-escugen-to-develop-next-generation-adcs-302019573.html
https://www.prnewswire.com/news-releases/inxmed-releases-data-demonstrating-ifebemtinib-in10018-trending-toward-survival-benefit-at-esmo-2023-301963834.html
https://www.prnewswire.com/news-releases/inxmed-presents-new-data-at-14th-annual-world-adc-highlighting-synergy-of-in10018-with-adcs-and-novel-stroma-targeting-pipeline-301960551.html
https://www.prnewswire.com/news-releases/inxmed-receives-approval-to-initiate-phase-i-clinical-trial-in-china-for-omtx705-a-first-in-class-fap-targeting-adc-301913209.html
https://www.prnewswire.com/news-releases/genequantum-and-inxmed-have-reached-a-technology-licensing-collaboration-providing-strong-support-for-innovative-adc-drug-research-and-development-301878259.html
https://www.prnewswire.com/news-releases/inxmed-in10018-at-asco-2022-demonstrates-robust-efficacy-in-patients-with-platinum-resistant-recurrent-ovarian-cancer-301557108.html
https://www.finsmes.com/2022/05/inxmed-raised-15m-in-series-b-financing.html
https://www.prnewswire.com/news-releases/inxmed-raised-15-million-in-series-b-financing-to-advance-innovative-therapies-to-drug-resistant-cancers-301542238.html
https://www.prnewswire.com/news-releases/inxmed-fak-inhibitor-in10018-received-breakthrough-therapy-designation-by-the-china-national-medical-products-administration-for-platinum-resistant-ovarian-cancer-301525013.html
Market Place
Share 
